Part ofHealthcare →

HR5547FEDERALIN_COMMITTEE

Maintaining Investments in New Innovation Act (H.R. 5547)

Original title: Maintaining Investments in New Innovation Act

December 17, 2024

Healthcare Pharmaceuticals Genetics Social Security Act Drug Pricing

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced

Committee

Floor Vote

Passed

Signed

Currently IN_COMMITTEE. The next step in the legislative lifecycle is Floor Vote.

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

The bill changes the timeline for when the federal government can begin negotiating prices for advanced genetic therapies, potentially delaying price regulation for these drugs by four years to encourage continued investment in genetic technology.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Pharmaceutical companies developing genetic therapies

These companies would have a longer period of market exclusivity before their products are subject to federal price negotiations.

Medicare program

The program's ability to negotiate prices for specific advanced drugs is delayed by four years under this proposal.

What changed

Current stage: IN_COMMITTEE.

What's next

Floor Vote.

Background

The Social Security Act includes provisions that allow the federal government to negotiate prices for certain high-cost drugs that have been on the market for a specific number of years. context

Summary

This bill extends the period of time that certain advanced, genetically targeted drugs are protected from government price negotiations under the Social Security Act. It increases the exclusivity period for these specific products from 7 years to 11 years.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

Frequently Asked Questions

What is an 'advanced drug product' under this bill?

It is a drug that uses to modulate the function of a gene or its associated gene product.

How does this bill change current drug pricing rules?

It adds 4 years to the existing 7-year period during which certain advanced drugs are exempt from federal price negotiations, totaling 11 years of protection.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Lobbying Activity

IONIS PHARMACEUTICALS, INC.

$150,000

View filing →

Related Legislation

Federal Bill85% related

Proposed Changes to Medicare Coverage for New Medical Technologies

This bill would allow Medicare Advantage plans to offer coverage for certain medical devices and technologies that currently fall outside standard Med

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift100% confidence

Extension of Exclusivity

The bill specifically targets 'advanced drug products' for a longer period of protection from price negotiation than standard drugs.

Social Security Act

Connected Entities

personMr. Nickel“Sponsor of the bill”Map →

organizationCommittee on Energy and Commerce“Committee responsible for consideration”Map →

personMr. Joyce of Pennsylvania“Co-sponsor of the bill”Map →

organizationCommittee on Ways and Means“Committee responsible for consideration”Map →

bill_numberH.R. 5547“Bill number”Map →

personMr. Davis of North Carolina“Co-sponsor of the bill”Map →

other118th Congress“Congress session”Map →

organizationU.S. Government Publishing Office“Source of the document”Map →

Analysis Score

0–100

Significance65
How much this matters to a regular citizen
Controversy50
Intensity of disagreement among stakeholders
Entertainment5
Compellingness for a non-policy-wonk reader
Buzz20
Current news / social attention level

Publisher tools